Neuren Pharmaceuticals Confirms Compliance With ASX Listing Rules; Shares Down 4%
MT Newswires Live
Jan 19
Neuren Pharmaceuticals (ASX:NEU) confirmed compliance with the listing rules of the Australian Securities Exchange (ASX), in particular, listing rule 3.1, after the company disclosed that its Nasdaq-listed partner forecasts Rett Syndrome drug global net sales of $700 million in 2028, according to a Monday Australian bourse filing.
In response to an ASX query, the company said it complies with the rule, which mandates it to immediately disclose any information to the bourse that can reasonably be expected to affect its share price.
The company's shares fell 4% in recent Monday trade.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.